Ophthalmogenetics and Gene Therapy

Ophthalmic hereditary qualities are worried about the hereditary commitment to ophthalmic illness, including assurance of examples and dangers of legacy, and in addition finding, visualization, and advancement of medications for hereditary variations from the norm. The advances in gene therapy maintain extensive promise for the cure of ophthalmic conditions. Gene therapy is additionally in a position to deal with primary open-angle glaucoma (POAG) in animal models, and research show it is economically viable. Genes may additionally be delivered into cells in vitro or in vivo making use of viral or non-viral vectors. Recent technical advances have led to the demonstration of the molecular basis of a range of ocular diseases.

  • Genetics of Myopia Development
  • Gene Therapy
  • Usher syndrome
  • Familial exudative vitreal retinopathy
  • Retinoblastoma
  • Leber hereditary optic neuropathy (LHON)
  • Optic atrophy
  • Genetics of Myopia Development

Related Conference of Ophthalmogenetics and Gene Therapy

February 17-18, 2025

11th Global Ophthalmology Meeting

Amsterdam, Netherlands
February 24-25, 2025

9th World Congress on Eye and Vision

Madrid, Spain
March 17-18, 2025

39th European Ophthalmology Congress

Berlin, Germany
April 07-08, 2025

6th World congress on Ophthalmology and Optometry

Amsterdam, Netherlands
April 29-30, 2025

35th International Congress on Vision Science and Eye

Barcelona, Spain
April 29-30, 2025

6th World Congress on Ophthalmology and Vision Science

Barcelona, Spain
June 12-13, 2025

6th International Conference on Optometry

London, UK

Ophthalmogenetics and Gene Therapy Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in